In this line, it has been shown that bortezomib inhibits tumor adaptation to hypoxia by repressing HIF-1α expression and sensitizes cancer cells in hypoxia [22], supporting the combination of TFP and proteasome inhibitors for treating hypoxic tumors such as PDAC. Here, HIF1A is linked to neoplasm.